Fiscal first-quarter 2017 earnings gave investors some signs of encouragement.
News & Analysis: Anavex Life Sciences
The tiny biotech's only clinical-stage candidate is a long way from the goal line, making these two biotech stocks far better picks.
These charts show where things stand -- and where they could be headed -- for Alzheimer's disease drug developer Anavex Life Sciences.
Biogen explorers the potential of Anavex's lead drug.
Here’s what Biogen’s deal with Anavex Life Sciences means, and what it doesn’t.
Here are a few missteps that might push the filing of a new drug application for its Alzheimer's disease candidate further into the future.
The market has pummeled both clinical-stage biotech stocks following bad news for their lead candidates. Find out which is most attractive now.
Disappointing Phase 2a study results from Anavex's lead compound sends its shares reeling.
Preclinical data powers Anavex in June, but plenty of risks remain.
There are plenty of reasons to be hopeful for Anavex Life Sciences, but each should be taken with a grain of salt.